狼人治疗
集合包含狼人治疗专家
专家集合是analyst-curated列表,突出了公司你需要知道的最重要的技术空间。
狼人疗法是包含在1专家收集,包括生物制药技术。
生物制药技术
5241件
公司参与研究、开发和商业化的化学或生物衍生& theranostic治疗药物。不包括维生素/补充剂,横/临床试验服务。
狼人治疗专利
狼人疗法已经提出12项专利。
3最受欢迎的专利主题包括:
- 集群的区别
- 免疫系统
- 免疫学
申请日 |
授予日期 |
标题 |
相关的话题 |
状态 |
---|---|---|---|---|
11/10/2021 |
12/27/2022 |
集群的分化、单克隆抗体、免疫学、免疫系统,白细胞介素 |
格兰特 |
申请日 |
11/10/2021 |
---|---|
授予日期 |
12/27/2022 |
标题 |
|
相关的话题 |
集群的分化、单克隆抗体、免疫学、免疫系统,白细胞介素 |
状态 |
格兰特 |
最新的狼人治疗新闻
2023年6月1日
水城,马萨诸塞州,美国水城、质量。,June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7th-9th, 2023, in New York, NY. A link to the live webcast of the presentation will be available at https://investors.werewolftx.com/news-and-events/events . An archived replay will be available for approximately 90 days following the event. About Werewolf Therapeutics: Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. To learn more visit www.werewolftx.com . Investor Contact:
狼人治疗常见问题(FAQ)
狼人疗法是何时成立的?
狼人疗法成立于2017年。
狼人治疗的总部在哪里?
狼人治疗的总部位于Talcott大街200号,水城。
狼人治疗的最新一轮融资是什么?
狼人治疗的最新一轮融资是上市。
狼人治疗筹集了多少钱?
狼人治疗筹集了总计128美元。
狼人治疗的投资者是谁?
狼人治疗的投资者包括Taiho Ventures MPM资本,UPMC企业、直流投资伙伴,洛伍德基金和11个。